Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   42559   clinical trials with a EudraCT protocol, of which   7007   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    Select Age Range:
    Select Trial Status:
    Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    2,921 result(s) found. Displaying page 1 of 147.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2017-004506-18 Sponsor Protocol Number: LYMRIT-37-07 Start Date*: 2018-06-13
    Sponsor Name:Nordic Nanovector ASA
    Full Title: A phase 2 open-label study of Betalutin in combination with rituximab in patients with relapsed/refractory follicular lymphoma (Archer-1)
    Medical condition: Follicular lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004148-53 Sponsor Protocol Number: M18ICR Start Date*: 2019-03-19
    Sponsor Name:NKI-AVL
    Full Title: ICRA (Improve Checkpoint-blockade Response in Advanced urothelial cancer), an adaptive clinical study to determine efficacy of combining weekly paclitaxel with tremelimumab +/- durvalumab (MEDI4736)
    Medical condition: Metastatic urothelial carcinoma patients or patients with irresectable disease who were previously treated with chemotherapy - or are cisplatin-ineligible - and have progressed during or after trea...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10022880 Invasive bladder cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003958-16 Sponsor Protocol Number: NL63056.018.17 Start Date*: 2018-08-10
    Sponsor Name:Academic Medical Center, University of Amsterdam
    Full Title: Effect of Reslizumab on small airways in asthma. RESSAPEA
    Medical condition: 1. Patients with severe eosinophilic asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003088-79 Sponsor Protocol Number: ABR66722 Start Date*: 2018-11-27
    Sponsor Name:Radboudumc
    Full Title: First line Lutetium-177-PSMA-617 radioligand therapy in metastatic castrate resistant prostate cancer.
    Medical condition: Patients with mCRPC, PSMA expressing, clinical and/or radiological progressive castrate resistant metastatic prostate cancer without any previous disease related systemic therapy.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000565-36 Sponsor Protocol Number: 38/2018 Start Date*: 2018-06-05
    Sponsor Name:University of Oulu
    Full Title: Paracetamol and ibuprofen/indomethacin in closing persistent ductus arteriosus
    Medical condition: Patent ductus arteriosus of a premature infant
    Disease:
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004978-34 Sponsor Protocol Number: RBHP2017BACHOUMAS Start Date*: 2018-12-04
    Sponsor Name:CHU de Clermont-ferrand
    Full Title: Efficacy of Testosterone gel to restore normal serum values of testosterone during the acute phase of critical illness in adult ICU patients. An open-label parallel randomized controlled pilot study
    Medical condition: - Hypermetabolism in ICU, loss of muscle mass and functional disability after ICU - ICU acquired hypogonadism - Treatment with testosterone gel in ICU
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004529-17 Sponsor Protocol Number: YO39609 Start Date*: 2018-07-17
    Sponsor Name:F. Hoffman-La Roche Ltd
    Full Title: A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED, UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH LOCALLY ADVANCED UNRESE...
    Medical condition: Locally advanced unresectable or Metastatic gastric or gastroesophageal junction cancer or esophageal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062878 Gastrooesophageal cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030151 Oesophageal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-003253-41 Sponsor Protocol Number: PMC008 Start Date*: 2018-09-11
    Sponsor Name:Polish Myeloma Consortium
    Full Title: PRE-emptive DAratumumab Therapy Of minimal Residual disease reappearance or biochemical relapse in multiple myeloma (PREDATOR).
    Medical condition: Multiple Myeloma and Minimal Residual Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000875-34 Sponsor Protocol Number: MM1807 Start Date*: 2018-05-30
    Sponsor Name:National Center for Cancer Immune Therapy
    Full Title: Efficacy of immunotherapy in melanoma patients with brain metastases treated with steroids
    Medical condition: Metastatic melanoma with brain metastasis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001440-18 Sponsor Protocol Number: IACI2016 Start Date*: 2018-05-30
    Sponsor Name:university medical center utrecht
    Full Title: Pharmacokinetic interactions between ivacaftor and cytochrome P450 3A4 inhibitors in cystic fibrosis patients and healthy controls
    Medical condition: cystic fibrosis and healthy subjects
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004564-35 Sponsor Protocol Number: 205739 Start Date*: 2018-08-14
    Sponsor Name:GlaxoSmithKline Research and Development Ltd.
    Full Title: A Phase IIa Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study to Investigate the Clinical Efficacy, Safety, and Tolerability of Nemiralisib (GSK2269557) in Symptomatic COPD Particip...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)/chronic bronchitis and emphysema
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10010953 COPD exacerbation LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) NL (Prematurely Ended) ES (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-003008-30 Sponsor Protocol Number: 16/0730 Start Date*: 2020-07-01
    Sponsor Name:University College London
    Full Title: A double-blind, randomised, placebo-controlled single-site study of high dose simvastatin treatment for secondary progressive multiple sclerosis: impact on vascular perfusion and oxidative damage
    Medical condition: Multiple Sclerosis (Secondary Progressive)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10052785 Multiple sclerosis acute and progressive HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-003943-20 Sponsor Protocol Number: DX-2930-03 Start Date*: 2016-03-31
    Sponsor Name:Dyax Corp., an indirect, wholly-owned subsidiary of Shire plc.
    Full Title: HELP Study™: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate DX 2930 For Long-Term Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE)
    Medical condition: Hereditary angioedema (HAE)
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004850 10075280 Hereditary angioedema attack LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004903-33 Sponsor Protocol Number: IBM4809 Start Date*: 2018-06-18
    Sponsor Name:Orphazyme A/S
    Full Title: Phase 2/3 Study of Arimoclomol in Inclusion Body Myositis (IBM) A Randomized, Double-blind, Placebo-Controlled Trial
    Medical condition: Sporadic Inclusion Body Myositis (sIBM)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004859 10075052 Sporadic inclusion body myositis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-000010-38 Sponsor Protocol Number: PAEDMED_v1.0 Start Date*: 2018-03-20
    Sponsor Name:Department of Clinical Pharmacology/Medical University of Vienna
    Full Title: Development of intravascular microdialysis as a tool for therapeutic drug monitoring in children.
    Medical condition: cohort A: We will administer a single dose of vancomycin, cefuroxime or gentamicin to healthy volunteers. The administration of the antibiotics in cohort A is for study purposes only. cohort B: We...
    Disease:
    Population Age: Infants and toddlers, Children, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000299-13 Sponsor Protocol Number: NVD003-CLN01 Start Date*: 2018-05-17
    Sponsor Name:Novadip Biosciences
    Full Title: A prospective multicentre single-arm study in adults to evaluate the safety and preliminary efficacy of the autologous 3D osteogenic implant NVD-003 for bone reconstruction for the treatment of rec...
    Medical condition: Patients with documented recalcitrant lower limb nonunion, meaning a single, meta- and/or diaphyseal nonunion defect of femur or tibia after at least one failed reconstructive surgical attempt.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing) LU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003112-53 Sponsor Protocol Number: TIP Start Date*: 2018-10-01
    Sponsor Name:Vejle Hospital
    Full Title: Predictive value of in-vitro testing anti-cancer therapy sensitivity on tumoroids from patients with metastatic pancreatic cancer
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033605 Pancreatic cancer metastatic LLT
    20.0 100000004864 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000307-17 Sponsor Protocol Number: 69HCL16_0743 Start Date*: 2018-07-19
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Microcirculatory and Macrocirculatory Effects of Landiolol on Postoperative Atrial Fibrillation: a Randomized Study. MMELPOAF study.
    Medical condition: Postoperative Atrial Fibrillation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000016-19 Sponsor Protocol Number: PSCs Start Date*: 2018-04-04
    Sponsor Name:Universitair ziekenhuis Brussel
    Full Title: Randomized comparative double blind prospective study with hyperbaric prilocaine 2 % and 3 different doses of sufentanil for elective caesarean section.
    Medical condition: Healthy pregnant women
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000482-36 Sponsor Protocol Number: CL02-ORY-1001AML Start Date*: 2018-09-07
    Sponsor Name:Oryzon Genomics S. A.
    Full Title: A pilot study to assess the safety, tolerability, dose finding and efficacy of ORY-1001 in combination with azacitidine in older patients with AML in first line therapy.
    Medical condition: Patients with acute mieloyd leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10024349 Leukemia myeloid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2022 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA